Bethesda transfusion therapy company raises $2.7 million
A Bethesda medical technology company focused on developing innovations in the transfusion industry has raised $2.7 million in an equity funding round. Hemanext, which changed its corporate name in October from New Health Sciences Inc., was seeking to raise a total of $5 million, a Securities and Exchange Commission filing shows. Hemanext did not specify was the proceeds of the funding will be used for. I've reached out to Hemanext for comment a nd will update this story when I hear back. The company… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - December 20, 2017 Category: American Health Authors: Tina Reed Source Type: news

Terumo launches Mirasol pathogen reduction tech trial
This study is intended as a step towards improving transfusion therapy and transfusion safety in the U.S. We’re excited to be a part of this study that hopefully will lead to measures that could further protect the nation’s blood supply from certain complications and threats of blood transfusions,” Miplate lead investigator Dr. Sherrill Slichter of Bloodworks Northwest said in a prepared statement. The study is expected to take 3.5 years and will include involvement from up to 15 hospitals and blood centers as well as 556 patients, the company said. Eligible patients in the trial will have a pla...
Source: Mass Device - May 17, 2017 Category: Medical Devices Authors: Fink Densford Tags: Blood Management Clinical Trials Terumo Source Type: news